Published by Stephanie Sutton, PharmTech Europe on July 22, 2011
under R&D
Most of you are probably enjoying the summer weather. Unfortunately, I’m based in the UK where June and July have been saturated with wet windy days. To add to the wintery feeling, this week I’ve read a lot in the news about flu vaccines. Just as some of us in the north of England have already accepted that summer is over (before it began I might add), vaccine manufacturers are also preparing for this winter’s round of seasonal influenza. Read more »
Published by Stephanie Sutton, PharmTech Europe on February 11, 2011
under Europe News
A possible link between cases of the chronic sleep disorder narcolepsy and GlaxoSmithKline’s H1N1 pandemic vaccine, Pandemrix, has led to a call from the World Health Organization (WHO) for further investigation. Narcolepsy is a rare condition with no currently available cure. Read more »
Published by Alexis Pellek on September 24, 2009
under Biotech, Manufacturing, North America News, Products, R&D, Trends
Following up on last week’s post, it appears that the H1N1 flu vaccine is effective in older children, ages 10 to 17, based on preliminary results of an ongoing trial. This week, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced that early results of clinical studies of the vaccine “look promising.” Read more »
Published by Alexis Pellek on September 18, 2009
under Biotech, Manufacturing, North America News, Products, R&D, Trends
The US Food and Drug Administration approved on Tuesday four H1N1 flu vaccines that demonstrated in clinical studies that a single dose produced a strong immune response in healthy adults after 8–10 days. Based on the manufacturers’ production schedules, things seem to be on track for vaccines to be available in four weeks.
But clinical trials of the vaccine are still underway on pregnant women and children, two groups that the Centers for Disease Control and Prevention (CDC) says are especially vulnerable to the H1N1 flu. Read more »
Published by Erik Greb on September 14, 2009
under Biotech, Drug Delivery, Formulation, Manufacturing, R&D, Trends
Have you ever considered getting a flu shot but quailed at the sight of the needle? Lots of people hate getting injections, but this delivery method is still the predominant technique for administering biological drugs. Rising demand for vaccines and other biologicals is one factor spurring manufacturers to seek alternative delivery methods that could one day rescue the needlephobic. Read more »
Published by Alexis Pellek on June 25, 2009
under Products, Trends
German authorities busted a counterfeit-drug ring yesterday selling fake Viagra (Pfizer, New York) via Internet pharmacy websites, according to an Agence France-Presse report. After a months-long investigation involving 60 customs officers, seven prosecutors and 25 tax investigators, raids in five cities produced 46,000 counterfeit Viagra tablets, frozen bank accounts in Austria, Switzerland, Spain, Belgium, France, and Turkey, four confiscated luxury vehicles, 15,000 euros ($21,000) in cash, and four people in police custody. Read more »
Published by Maribel Rios on June 11, 2009
under Biotech, Trends
For the first time in 41 years, the world is at the start of an influenza pandemic. The announcement regarding raising the H1N1 influenza pandemic level from Level 5 to Level 6 came today from from Dr. Margaret Chan, director general of the World Health Organization. Read more »
Published by Maribel Rios on May 26, 2009
under Biotech, Manufacturing, R&D
The United States Department of Health and Human Services (HHS) is trying to cover all of its bases as it seeks to stockpile a vaccine to fight influenza A (H1N1). GSK and Sanofi are first on the list of drugmakers that will work with HHS to meet its objectives. Research scientists are also preparing for possible drug-resistant strains by making progress toward a new type of drug that will be able to stop the spread of infection and possibly prevent initial infection. Read more »
Published by Angie Drakulich on May 13, 2009
under Biotech, Europe News, Products
In response to the swine-flu outbreak, the European Medicines Agency (EMEA) last week authorized the use of Tamiflu (oseltamivir) capsules up to two years after the drug’s prescribed expiration dates. EMEA’s Committee for Medicinal Products for Human Use (CHMP) specifically extended the shelf-life of Tamiflu 75 mg, 45 mg, and 30 mg hard capsules from 5 to 7 years. Read more »
Published by Patricia Van Arnum on May 1, 2009
under Trends
As my colleague Maribel Rios discussed in her blog this week, the recent outbreak of swine flu gives us pause to consider our pandemic preparedness. The events of this past week also makes us more aware of the interrelationships and complexity of global public health, giving rise to an even broader question, has the pharmaceutical industry as a whole met its responsibility in effectuating global public health? Read more »
Next Page »